Recent research indicates GLP-1 medications, such as Ozempic and Wegovy, not only facilitate weight loss but also significantly decrease alcohol consumption in patients. A study by a team from University College Dublin revealed an average drop in alcohol intake from 11.3 to 4.3 drinks weekly among participants. This research, conducted on 262 overweight or obese adults, explores how these drugs can mitigate obesity-related complications while potentially lowering alcohol usage, indicating a dual benefit for individuals managing both weight and consumption issues.
"GLP-1 [drugs] have been shown to treat obesity and reduce the risk of multiple obesity-related complications," said Professor Carel le Roux of University College Dublin in Ireland. "The beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results."
Volunteers reported their alcohol habits before the study began and were split into three groups. Most of the participants were female, the average age was 46 and the average weight was 216 pounds.
Average alcohol intake decreased from 11.3 to 4.3 drinks a week, a reduction of almost two-thirds. Among the regular drinkers, consumption declined from 23.2 to 7.8 drinks a week.
None of the participants drank more than usual during that time. The researchers followed 188 of the 262 patients for an average of four months of treatment.
Collection
[
|
...
]